IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v7y2006i2p86-95.html
   My bibliography  Save this article

Costs and quality of life of multiple sclerosis in Switzerland

Author

Listed:
  • Gisela Kobelt
  • Jenny Berg
  • Peter Lindgren
  • Andrea Gerfin
  • J. Lutz

Abstract

No abstract is available for this item.

Suggested Citation

  • Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz, 2006. "Costs and quality of life of multiple sclerosis in Switzerland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 86-95, July.
    • Handle: RePEc:spr:eujhec:v:7:y:2006:i:2:p:86-95
    DOI: 10.1007/s10198-006-0383-9
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-006-0383-9
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-006-0383-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Paul Dolan & Claire Gudex & Paul Kind & Alan Williams, 1995. "A social tariff for EuroQol: results from a UK general population survey," Working Papers 138chedp, Centre for Health Economics, University of York.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Fernando Gracia & Mario Larreategui & Gaudencio Rodríguez & Aaron Benzadón & Michelle Ortiz & Divian Morales & Claudia Domínguez & Rosa Enith Carrillo & Carlos Valderrama & Luís Lizán & Blas Armién, 2018. "Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    2. Olivia Ernstsson & Hanna Gyllensten & Kristina Alexanderson & Petter Tinghög & Emilie Friberg & Anders Norlund, 2016. "Cost of Illness of Multiple Sclerosis - A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-25, July.
    3. Oliver Findling & Magdalena Baltisberger & Simon Jung & Christian P Kamm & Heinrich P Mattle & Johann Sellner, 2015. "Variables Related to Working Capability among Swiss Patients with Multiple Sclerosis—A Cohort Study," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-9, April.
    4. A. J. Hawton & C. Green, 2016. "Multiple sclerosis: relapses, resource use, and costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(7), pages 875-884, September.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Nick Bansback & Huiying Sun & Daphne P. Guh & Xin Li & Bohdan Nosyk & Susan Griffin & Paul G. Barnett & Aslam H. Anis, 2008. "Impact of the recall period on measuring health utilities for acute events," Health Economics, John Wiley & Sons, Ltd., vol. 17(12), pages 1413-1419.
    2. MerriKay Oleen-Burkey & Jane Castelli-Haley & Maureen Lage & Kenneth Johnson, 2012. "Burden of a Multiple Sclerosis Relapse," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 5(1), pages 57-69, March.
    3. David G. T. Whitehurst & Stirling Bryan & Martyn Lewis, 2011. "Systematic Review and Empirical Comparison of Contemporaneous EQ-5D and SF-6D Group Mean Scores," Medical Decision Making, , vol. 31(6), pages 34-44, November.
    4. R. McQueen & Samuel Ellis & David Maahs & Heather Anderson & Kavita Nair & Anne Libby & Jonathan Campbell, 2014. "Association Between Glycated Hemoglobin and Health Utility for Type 1 Diabetes," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 7(2), pages 197-205, June.
    5. Petrie, Dennis & Doran, Chris & Shakeshaft, Anthony & Sanson-Fisher, Rob, 2008. "The relationship between alcohol consumption and self-reported health status using the EQ5D: Evidence from rural Australia," Social Science & Medicine, Elsevier, vol. 67(11), pages 1717-1726, December.
    6. Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 55-64, July.
    7. McNamee, Paul, 2007. "What difference does it make? The calculation of QALY gains from health profiles using patient and general population values," Health Policy, Elsevier, vol. 84(2-3), pages 321-331, December.
    8. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
    9. Lyttkens, Carl Hampus & Gerdtham, Ulf-G. & Tinghög, Gustav, 2018. "Do We Know What We Are Doing? An Exploratory Study on Swedish Health Economists and the EQ-5D," Working Papers 2018:40, Lund University, Department of Economics.
    10. Lieven Annemans & Mélanie Brignone & Sylvain Druais & Ann Pauw & Aline Gauthier & Koen Demyttenaere, 2014. "Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium," PharmacoEconomics, Springer, vol. 32(5), pages 479-493, May.
    11. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 65-74, July.
    12. José Nunes, 1998. "Economic evaluation of rehabilitation: The quality of life approach using EuroQol," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 4(2), pages 192-201, May.
    13. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
    14. Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass, 2006. "Costs and quality of life of multiple sclerosis in Austria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 14-23, July.
    15. Lena Lundberg & Magnus Johannesson & Dag G.L. Isacson & Lars Borgquist, 1999. "The Relationship between Health-state Utilities and the SF-12 in a General Population," Medical Decision Making, , vol. 19(2), pages 128-140, April.
    16. Richard Holland & Richard D Smith & Ian Harvey & Louise Swift & Elizabeth Lenaghan, 2004. "Assessing quality of life in the elderly: a direct comparison of the EQ‐5D and AQoL," Health Economics, John Wiley & Sons, Ltd., vol. 13(8), pages 793-805, August.
    17. Adrian Bagust & Sophie Beale, 2005. "Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 217-230, March.
    18. Madlaina Costa-Scharplatz & Björn Ställberg & Pankaj Goyal & Yumi Asukai & Jean-Bernard Gruenberger & David Price, 2015. "Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 637-645, December.
    19. Karen Gerard & Katharine Johnston & Jackie Brown, 1999. "The role of a pre‐scored multi‐attribute health classification measure in validating condition‐specific health state descriptions," Health Economics, John Wiley & Sons, Ltd., vol. 8(8), pages 685-699, December.
    20. An Tran-Duy & Annelies Boonen & Wietske Kievit & Piet Riel & Mart Laar & Johan Severens, 2014. "Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 32(10), pages 1015-1028, October.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:7:y:2006:i:2:p:86-95. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.